More often than not, takeover speculation can give a lively boost -- at least in the short term -- to a company's stock. That ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away Eli Lilly's weight-loss drug Zepbound is on track to be the world's ...

Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis and Sanofi have agreed to drug ...

AbbVie stock fell after denying Revolution Medicines buyout talks. Company also cut 2025 earnings forecast to $9.90-$9.94 per ...

The drug and biotech sector has recovered in the past couple of months after remaining muted for most of this year. The recovery began with large drugmakers like Pfizer and AstraZeneca signing drug ...

After a sluggish first half, the drug and biotech sector has staged a recovery over the past two to three months. This ...

The global weight loss drug market, perhaps ironically, is growing like gangbusters these days. Globally, it’s set to expand from $15 billion in 2024 to $150 billion by 2035, according to Morgan ...

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024. Objective: To examine how drug manufacturers disclosed prices for new ...